HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VCYT
Veracyte, Inc.
VCYT's fundamentals are strong and it looks cheap: trading at 16x earnings, less than half its usual 65x. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VCYT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
VCYT's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VCYT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 16x | $24.63 | — |
| Forward | 16x | $24.63 | — |
| Cheap | 35x | $54.07 | +120% |
| Fair | 64x | $99.04 | +302% |
| Expensive | 105x | $162 | +558% |
Historical ranges are pointers, not guarantees.
VCYT's PE is in its cheap range at 16.0x. On analysts' estimates for next year's earnings, today's price would be 16.2x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VCYT Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect VCYT's revenue to grow, but its profitability to weaken.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VCYT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | -1.2% |
| Q3 2026 | $1.54 | +295% |
| Q2 2026 | $1.40 | +312% |
| Q1 2026 | $1.08 | +157% |
| Q4 2025 | $0.82 | +165% |
| Q3 2025 | $0.39 | +$0.53 |
| Q2 2025 | $0.34 | +$1.08 |
| Q1 2025 | $0.42 | +$1.35 |
| Q4 2024 | $0.31 | +$1.33 |
VCYT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VCYT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
VCYT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $151.8M | +15% |
| Q2 2026 | $150.3M | +15% |
| Q1 2026 | $139.1M | +21% |
| Q4 2025 | $140.6M | +19% |
| Q3 2025 | $131.9M | +14% |
| Q2 2025 | $130.2M | +14% |
| Q1 2025 | $114.5M | +18% |
| Q4 2024 | $118.6M | +21% |
VCYT's revenue has grown year over year every quarter since late 2020: $152M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -6.5 points |
| Q2 2026 | 15% | +19 points |
| Q1 2026 | 16% | +14 points |
| Q4 2025 | 26% | +23 points |
| Q3 2025 | 17% | +7 points |
| Q2 2025 | -4% | -8.1 points |
| Q1 2025 | 2.5% | +7.3 points |
| Q4 2024 | 3.5% | +40 points |
VCYT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
VCYT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | -9.6% |
| Q2 2026 | $43M | +33% |
| Q1 2026 | $32.3M | +810% |
| Q4 2025 | $48.8M | +139% |
| Q3 2025 | $42M | +51% |
| Q2 2025 | $32.3M | +21% |
| Q1 2025 | $3.5M | +$14.6M |
| Q4 2024 | $20.4M | +56% |
VCYT generated $162M in free cash flow over the past year, up 65% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VCYT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VCYT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +724K shares |
| 1 year | +3.9% | +3.1M shares |
| 3 years | +14% | +10M shares |
| 5 years | +19% | +13M shares |
| Available history | +69% | +33.7M shares |
VCYT has 83M diluted shares, up 3.9% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VCYT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -2.4x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -6.7x | Net Cash |
| Q2 2025 | -6.0x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -6.0x | Net Cash |
VCYT has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VCYT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 23.4 | Neutral |
VCYT's weekly RSI is 33 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VCYT PE vs Healthcare Sector
| Metric | VCYT | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 26x | 38% below |
| PE % | 1 | 29 | 28 pts below |
VCYT is trading at 16x earnings, a 38% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VCYT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.8 | 40% below |
| 20 week MA | $45.0 | 45% below |
| 50 week MA | $41.9 | 41% below |
| 100 week MA | $37.8 | 35% below |
| 200 week MA | $31.8 | 23% below |
VCYT is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VCYT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $55.8 | +92% |
| 2021 | $55.8 | $40.5 | -27% |
| 2022 | $40.5 | $24.6 | -39% |
| 2023 | $24.6 | $27.5 | +12% |
| 2024 | $27.5 | $40.1 | +46% |
| 2025 | $40.1 | $42.5 | +5.9% |
| 2026 YTD | $42.5 | $24.6 | -42% |
VCYT has the edge over HIMS on returns for 2026, with the stronger performance.